Notable Labs

Notable Labs Asset Growth

The Year-over-Year Total Asset Growth of Notable Labs (NTBLQ) as of Nov 8, 2026 is -34.12 %. In the previous year, Year-over-Year Total Asset Growth was -54.13 % — a change of -36.97% (higher).

Asset Growth

-34.12 %

YoY

-36.97%

Last updated:

Year-over-Year Total Asset Growth of Notable Labs is 2023 -34.12 % . Year-over-Year Total Asset Growth of Notable Labs was 2022 -54.13 % . It decreases by -36.97% higher compared to the previous year.

The Notable Labs Asset Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Asset Growth
Date
Asset Growth
Jan 1, 2016
20.46 USD
Jan 1, 2017
38.97 USD
Jan 1, 2018
-7.63 USD
Jan 1, 2019
-19.23 USD
Jan 1, 2020
-14.89 USD
Jan 1, 2021
55.02 USD
Jan 1, 2022
-54.13 USD
Jan 1, 2023
-34.12 USD
The Notable Labs Asset Growth history
YEARAsset GrowthYoY
-34.12 %-36.97%
-54.13 %-198.38%
55.02 %-469.41%
-14.89 %-22.55%
-19.23 %+152.17%
-7.63 %-119.57%
38.97 %+90.42%
20.46 %+609.54%
2.88 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Notable Labs Stock analysis

What does Notable Labs do? Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company developing targeted medicines for cancer and immune-inflammatory diseases. The company leverages two platform technologies: Vascular Targeting System (VTS), a gene-based approach targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based method inhibiting monocyte migration. Its product candidates aim to improve patient outcomes by overcoming limitations of current treatments. The firm's pipeline focuses on difficult-to-treat conditions, with VTS and MTT serving as the core technologies for developing therapeutics. VTS targets cancer by focusing on blood vessel formation, while MTT addresses immune-inflammatory diseases through monocyte migration control. These technologies enable the creation of next-generation medicines that address unmet medical needs. Notable Labs Ltd sells its product candidates to pharmaceutical companies and healthcare providers for further development and clinical trials. The primary buyers are biopharmaceutical firms seeking innovative therapies, particularly those targeting cancer and immune-inflammatory conditions. The company's revenue model relies on licensing agreements and partnerships with these industry players to advance its pipeline. Notable Labs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Notable Labs stock

Year-over-Year Total Asset Growth of Notable Labs is -34.12 % in 2023.

On Eulerpool you can find the complete historical development of Year-over-Year Total Asset Growth Notable Labs since 2006 – with annual values, charts, and detailed analysis.

Asset growth measures the percentage change in total assets. Rapid asset growth may indicate expansion but can also correlate with lower future returns.

To evaluate Year-over-Year Total Asset Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Total Asset Growth.

Year-over-Year Total Asset Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Total Asset Growth's Notable Labs historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Notable Labs

All Key Metrics — Notable Labs